Structure Therapeutics Inc. Sponsored ADR $GPCR Position Increased by Squarepoint Ops LLC

Posted by Brian Himes on Sep 11th, 2026

Squarepoint Ops LLC grew its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 454.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 125,575 shares of the company’s stock after purchasing an additional 102,929 shares during the period. Squarepoint Ops LLC’s holdings in Structure Therapeutics were worth $6,740,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Sterling Capital Management LLC bought a new stake in shares of Structure Therapeutics during the 1st quarter valued at about $28,000. State of Wyoming bought a new position in Structure Therapeutics in the second quarter worth about $28,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Structure Therapeutics in the fourth quarter valued at approximately $127,000. Assetmark Inc. boosted its stake in Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after acquiring an additional 449 shares during the period. Finally, Banque Cantonale Vaudoise bought a new position in shares of Structure Therapeutics during the fourth quarter valued at approximately $205,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Trading Down 4.1%

Shares of NASDAQ:GPCR opened at $39.55 on Friday. The firm’s 50 day moving average is $49.92 and its two-hundred day moving average is $48.64. The firm has a market capitalization of $2.75 billion, a P/E ratio of -39.55 and a beta of -1.45. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $20.04 and a 52 week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wall Street Zen raised Structure Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $110.00 target price on shares of Structure Therapeutics in a research report on Wednesday. Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Finally, HC Wainwright reissued a “buy” rating on shares of Structure Therapeutics in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and an average price target of $110.91.

View Our Latest Analysis on GPCR

Structure Therapeutics Profile

(Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.